Some questions

Plus a little on "Who is Peter Halligan" for those interested!

Questions

For the WHO:

What is the stopping condition for the Public Health Emergency of International Concern (PHEIC – pronounced FAKE)

For the FDA

Same question on the stopping condition for the injections. BY law, an EUA is dependent on 50% effectiveness. It appears to now be NEGATIVE. How many doses could the EUA last for? How does the FDA check this on an on-going basis? Where is its reporting?

Are viral vector injections safer and more effective than mRNA injections? How has this been measured and monitored?

How many injection manufacturing plants has the FDA inspected and how frequently? (See HowBadisMyBatch for massive quality issues as measured by mortality outcomes by State). Quality assurance and inspections are required by federal law.

(Getting on for 90 million visitors in 2021 here: How Bad is my Batch . com ?

https://howbadismybatch.com Check out your State to see if your doses were up to 11 times worse than someone else’s deadliness!)

General curiosities (all answers welcome)

The spike protein attached to the virus is toxic, right? Why is injecting a payload that instructs the bodies immune system to manufacture the spike protein any less toxic?

How does the Rapid Antigen Test (RAT) or the latest versions of the RT-PCR test distinguish between spike proteins from an infection and the spike proteins caused by an injection?

Help needed! As I understand it, the spike protein is delivered in a programmed lipid nano-particle, coated with Polyethylene Glycol (PEG). Each of the4e three parts is toxic. How has the relative toxicity and side effects from each been clinically trialled, separately or in combination, with and without payloads?

As per the previous question, how is manufacturing, distribution and injection quality of the manufacturing process checked, where are the inspection reports? (More HowBadIsMyBatch issues).

China can make Human Ivermectin (IVM) for US$200 a kilo. A kilo ought to be enough to treat 8,333 people (10x12mg per treatment).  That works out at 2.5 US cents a dose – two for a US nickel.  It would take 120,000 kg costing $24 million to treat a billion people – less than $200 million for the IVM component of a treatment pack for the entire planet. That is before the billion or so people that might be already using IVM for other reasons in Africa, South, America, Latin America and Asia. On the same basis the IVM component of dosing China and India would cost under $34 million each, Russia $3.4 million, the EU under $11 million and the USA under $8.5 million.

Sheerherb Human Body Uses High-Quality Hot-Selling Ivermectin Capsules - China Ivermectin Drives Nematodes and Abamectin Derivatives (made-in-china.com)

https://1016706527.en.made-in-china.com/product/gFmTBsjPHrYA/China-Sheerherb-Human-Body-Uses-High-Quality-Hot-Selling-Ivermectin-Capsules.html

Maybe India makes it cheaper than China. Maybe Chinese or Indian IVM gets seized at ports of entry to the USA at Customs. For interest, I shipped in the most evil smelling natural treatment for shoulder pain from China – sort of a bunch of twigs that you boil and drink. (Unused). It arrived in the UK a few years ago after 6 weeks with only slight tampering!

Correctly dosed IVM has ZERO side effects. There are no harms inflicted from using it. We know why the US isn’t using it (vested Big Pharma interests, able to charge anywhere between $14 and $41 dollars per mRNA dose v 2.5 US cents for a course of ten x12 mg tablets) but why aren’t China, India and Russia solving their C19 issue using IVM?

As a reminder, the Indian State of Uttar Pradesh obliterated C19 in a few months with IVM treatment packs dispersed widely (where needed) on a prophylactic and “early to mid-stage cure” basis for US$ 5 per pack (the pack included a few other things). This scales to a cost of around US$7 billion for 1.4 billion people each for India and China.

I haven’t got a source for the cost of an HCQ+Zn+AzM pack or a Zelenko alternative, or any other alternative or that matter.

There are a multitude of other questions – some of which I have addressed in prior posts. Information is arriving all the time that fills out knowledge and expertise gaps – especially amongst those who are vastly more experienced and qualified in specialist fields than I.

There now follows a precis of some of my background

On a personal note - I liked playing and now enjoy watching Rugby Union. I left home at 16 and finally packed up working for others after 4 decades.

My last role was in the field of investment manager research, specializing in fixed income but also overseeing Target Date Funds, Index Tracking Funds of all sorts and providing some input into the balance sheet monitoring of the largest US Life Insurance companies. All tasks were completed within teams of some of the best people I have ever worked with.

For context, global Fixed Income Managers (I was the US Head of Global Fixed Income) made up around a fifth of the trillions of dollars of assets managed by the investment managers my company researched in order to provide advice to clients with several trillion dollars of, mostly, US and UK State and Corporate pension funds.

Some investment managers have dozens of products, and have trillions under management by operating in a few or many regions or globally, some just a few products and a few billion.

Each product of ach manager was researched separately. Researching each product of each manager required reviewing a “pack” of material running to 100’s of pages of data specific to that product. A pre-briefing of an hour was held by a few researchers to set the agenda for a three hour on-site meeting with the key investment personnel managing the product. After agreeing the agenda, the meeting was held at the managers office. Lots of travel.

After the meeting with the investment manager, the results were written up on a database with ratings recommendations along seven factors/dimensions plus an overall rating for these ratings recommendations to be voted by a committee of other researchers on the team (not by those doing the research with the manager).

The debrief team - usually of 5 or more researchers, would approve or adjust each rating as well as the overall rating (Buy/Hold/Sell). Every rated product for every manager was reviewed every three months or as needed for any significant developments.

Clients requiring managers to meet their allocations across different investment categories would be presented with the buy rated managers for the specific investment category and assisted on any “blending” of different styles within and across other asset categories (for example, if other fixed income or equity styles in use already conflicted or complemented the candidate fixed income manager style.

The performance of the investment manager research teams “buy lists”, relative to target excess returns for each separate investment category was a key marketing and remuneration consideration for the investment manager research teams.

This is the sort of research and analysis I expect as a minimum for any new product!

Prior to this 5 year + 3 year investment manager research (I took a break and switched from London to Chicago), I had operated in almost all fields in investment management (for Life, General and Reinsurance companies, Trust funds, (small) sub-Saharan African and Caribbean central banks plus a few years here and there as an investment consultant, interbank broker and licensed stock exchange operator. A key part of my very early career was managing a team that compiled and analysed the performance of multi-currency cash, bond and equity managers  for sovereign wealth funds. Latterly in that role, chairing monthly performance meetings of dealers and fund managers.

I hesitate to mention it, but I have an Executive MBA from Auckland City University Business School from 1990!